• 1
    Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type I in patient with tropical spastic paraparesis. Lancet 1985;2:40710.
  • 2
    Osame M, Usuku K, Izumo S et al. HTLV-I associated myelopathy: a new clinical entity. Lancet 1986;1:10312.
  • 3
    Takatsumi K, Uchiyama T, Sagawa K, Yodoi J. In Seno (es) topics in hematology. Amst Excerpta Medica 1977;1:737.
  • 4
    Uchiyama T. Human T-cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997;15:1537.
  • 5
    Hinuma Y, Cómoda H, Chosa T, et al. Antibodies to adult T-cell leucemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer 1982;29:6315.
  • 6
    Mochizuki M, Watanabe T, Yamaguchi K et al. Uveitis associated with human T-cell lymphotropic virus type I: seroepidemiologic, clinical and virologic studies. J Infect Dis 1992;166:9434.
  • 7
    Cruz BA, Catalan-Soares B, Proietti F. Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol 2006;33:23003.
  • 8
    Miyazawa M, Takahashi S, Kawaguchi H et al. Low expression of adhesion molecules in a case of cutaneous T-cell lymphoma. J Dermatol 1995;22:65964.
  • 9
    Smadja D, Bellance R, Cabre P, Kerjean J, Lezin A, Vernant JC. Atteintes du système nerveux périphérique et du muscle squelettique au cours des paraplégies associées au vírus HTLV-I; etude de 70 cas observes em Martinique. Ver Neurol (Paris) 1995;151:1905.
  • 10
    Nishioka K, Maruyama I, Sato K, Kitajima I, Makajima Y, Osame M. Chronic Inflammatory arthropathy associated with HTLV-I. Histopathology 1989;7:34964.
  • 11
    Catalan-Soares B, Carneiro-Proietti AB, Proietti FA. Interdisciplinary HTLV Research Group. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica 2005;21:92631.
  • 12
    Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8 +  T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001;50:80712.
  • 13
    Jacobson S. Immunopathogenesis of HTLV-I-associated neurologic disease. J Infect Dis 2002;186 (suppl 2):S18792.
  • 14
    Roman GC. Retrovirus-associated myelopathies. Intern Med 2001;40:147.
  • 15
    Hollesberg P, Hafler DA. Pathogenesis of diseases induced by HTLV-I Infection. N Engl J Med 1993;328:117382.
  • 16
    Ferreira JOC, Planelles V, Rosenblatt JD. Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Rev 1997;11:91104.
  • 17
    Franchini G. Molecular mechanisms of HTLV-I. Blood 1995;86:161939.
  • 18
    Montanheiro P, Penalva-de-Oliveira A, Posada-Vergada MP et al. HTLV-I proviral DNA viral load among asymptomatic patients and patients with TSP/HAM. Braz J Med Biol Res 2005;38:16437.
  • 19
    Höllsberg P. Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev 1999;63:30833.
  • 20
    Hanon E, Goon P, Taylor GP et al. High production of IFN-γ but not IL-2 by human T-lymphotropic virus type I-Infected peripheral blood mononuclear cells. Blood 2001;98:7216.
  • 21
    Brito-Melo GE, Peruhype-Magalhães V, Teixeira-Carvalho A et al. IL-10 produced by CD4 +  and CD8 +  T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection. Clin Exp Immunol 2007;147:3544.
  • 22
    Sabouri AH, Usuku K, Hayashi D et al. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8 +  T cells in HTLV-1-associated neurologic disease. Blood 2008;112:241120.
  • 23
    Croda MG, De Oliveira AC, Vergara MP et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci 2008;269:1337.